Meyka AI API is live for developers.Start building.
Advertisement
InflaRx N.V.

InflaRx N.V. Fundamental Analysis

IFRXNASDAQ
HealthcareBiotechnology
$1.84
$0.16(8.00%)
U.S. Market opens in 41h 52m
Advertisement

InflaRx N.V. Fundamental Analysis

InflaRx N.V. (IFRX) shows weak financial fundamentals with a PE ratio of -2.65, profit margin of -1463.04%, and ROE of -94.90%. The company generates $0.0B in annual revenue with weak year-over-year growth of -83.01%.

Key Strengths

Cash Position29.95%
PEG Ratio-0.17
Current Ratio4.16

Areas of Concern

ROE-94.90%
Operating Margin-1444.45%
We analyze IFRX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -109876.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-109876.7/100

We analyze IFRX's fundamental strength across five key dimensions:

Efficiency Score

Weak

IFRX struggles to generate sufficient returns from assets.

ROA > 10%
-87.68%

Valuation Score

Excellent

IFRX trades at attractive valuation levels.

PE < 25
-2.65
PEG Ratio < 2
-0.17

Growth Score

Moderate

IFRX shows steady but slowing expansion.

Revenue Growth > 5%
-83.01%
EPS Growth > 10%
15.38%

Financial Health Score

Excellent

IFRX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
4.16

Profitability Score

Weak

IFRX struggles to sustain strong margins.

ROE > 15%
-9489.75%
Net Margin ≥ 15%
-1463.04%
Positive Free Cash Flow
No

Key Financial Metrics

Is IFRX Expensive or Cheap?

P/E Ratio

IFRX trades at -2.65 times earnings. This suggests potential undervaluation.

-2.65

PEG Ratio

When adjusting for growth, IFRX's PEG of -0.17 indicates potential undervaluation.

-0.17

Price to Book

The market values InflaRx N.V. at 3.08 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.08

EV/EBITDA

Enterprise value stands at -3.02 times EBITDA. This is generally considered low.

-3.02

How Well Does IFRX Make Money?

Net Profit Margin

For every $100 in sales, InflaRx N.V. keeps $-1463.04 as profit after all expenses.

-1463.04%

Operating Margin

Core operations generate -1444.45 in profit for every $100 in revenue, before interest and taxes.

-1444.45%

ROE

Management delivers $-94.90 in profit for every $100 of shareholder equity.

-94.90%

ROA

InflaRx N.V. generates $-87.68 in profit for every $100 in assets, demonstrating efficient asset deployment.

-87.68%

Following the Money - Real Cash Generation

Operating Cash Flow

InflaRx N.V. generates limited operating cash flow of $-28.79M, signaling weaker underlying cash strength.

$-28.79M

Free Cash Flow

InflaRx N.V. generates weak or negative free cash flow of $-28.90M, restricting financial flexibility.

$-28.90M

FCF Per Share

Each share generates $-0.40 in free cash annually.

$-0.40

FCF Yield

IFRX converts -24.89% of its market value into free cash.

-24.89%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.65

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.17

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.08

vs 25 benchmark

P/S Ratio

Price to sales ratio

3879.35

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.16

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.95

vs 25 benchmark

ROA

Return on assets percentage

-0.88

vs 25 benchmark

ROCE

Return on capital employed

-1.13

vs 25 benchmark

How IFRX Stacks Against Its Sector Peers

MetricIFRX ValueSector AveragePerformance
P/E Ratio-2.6529.20 Better (Cheaper)
ROE-94.90%729.00% Weak
Net Margin-146303.92%-52856.00% (disorted) Weak
Debt/Equity0.020.49 Strong (Low Leverage)
Current Ratio4.164.43 Strong Liquidity
ROA-87.68%-20711.00% (disorted) Weak

IFRX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews InflaRx N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

54.49%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

62.65%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ